Evaluation of copper-dependent proteasome-inhibitory and apoptosis-inducing activities of novel pyrrolidine dithiocarbamate analogues

International Journal of Molecular Medicine

Volumn 20, Issue 6, 2007, Pages 919-925

  Yu, Zhiyong ^a,d   Wang, Fei ^b   Milacic, Vesna ^a   Li, Xiaofeng ^b   Cui, Qiuzhi Cindy ^a   Zhang, Bin ^b   Yan, Bing ^b,c   Dou, Q Ping ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SHANDONG UNIVERSITY   (China)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Apoptosis; Cancer; Drug discovery; Proteasome inhibitors; Pyrrolidine dithiocarbamate

Indexed keywords

COPPER; PROTEASOME; PYRROLIDINE DERIVATIVE; PYRROLIDINE DITHIOCARBAMIC ACID; THIOCARBAMIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL; APOPTOSIS; ARTICLE; CELL LINE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; PHYSIOLOGY; STRUCTURE ACTIVITY RELATION;

ANIMALS; APOPTOSIS; CELL LINE; CELL PROLIFERATION; COPPER; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MOLECULAR STRUCTURE; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRROLIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; THIOCARBAMATES;

EID: 42149187107     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.20.6.919     Document Type: Article

References (26)

1. Jacobson MD, Weil M and Raff MC: Programmed cell death in animal development. Cell 88: 347-354, 1997. (Pubitemid 27131376)
2. Thatte U and Dahanukar S: Apoptosis - clinical relevance and pharmacological manipulation. Drugs 54: 511-532, 1997. (Pubitemid 27464153)
3. Song Z and Steller H: Death by design: mechanism and control of apoptosis. Trends Cell Biol 9: M49-M52, 1999.
4. Orlowski RZ and Dees EC: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer. Breast Cancer Res 5: 1-7, 2003.
5. Ciechanover A: The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 17: 7151-7160, 1998.
6. Seemuller E, Lupas A, Stock D, Lowe J, Huber R and Baumeister W: Proteasome from Thermoplasma acidophilum: a threonine protease. Science 268: 579-582, 1995.
7. An B, Goldfarb RH, Siman R and Dou QP: Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 5: 1062-1075, 1998.
8. Lopes UG, Erhardt P, Yao R and Cooper GM: p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 272: 12893-12896, 1997.
9. Adams J: Potential for proteasome inhibition in the treatment of cancer. Drug Discov Today 8: 307-315, 2003. (Pubitemid 36332222)
10. Almond JB and Cohen GM: The proteasome: a novel target for cancer chemotherapy. Leukemia 16: 433-443, 2002.
11. Dou QP and Li B: Proteasome inhibitors as potential novel anticancer agents Drug Resist Update 2: 215-223, 1999.
12. Schreck R, Meier B, Mannel DN, Droge W and Baeuerle PA: Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J Exp Med 175: 1181-1194, 1992.
13. Malaguarnera L, Pilastro MR, DiMarco R, Scifo C, Renis M, Mazzarino MC and Messina A: Cell death in human acute myelogenous leukemic cells induced by pyrrolidine dithiocarbamate. Apoptosis 8: 539-545, 2003.
14. Parodi FE, Mao D, Ennis TL, Bartoli MA and Thompson RW: Suppression of experimental abdominal aortic aneurysms in mice by treatment with pyrrolidine dithiocarbamate, an antioxidant inhibitor of nuclear factor-kappaB. J Vasc Surg 41: 479-489, 2005.
15. Daniel KG, Chen D, Orlu S, Cui QC, Miller FR and Dou QP: Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Res 7: R897-R908, 2005.
16. Chen D, Peng F, Cui QC, Daniel KG, Orlu S, Liu J and Dou QP: Inhibition of prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate-copper complex is associated with suppression of proliferation and induction of apoptosis. Front Biosci 10: 2932-2939, 2005.
17. Clifford AM and Lichty JG: Esters of dithiocarbamic acids. J Am Chem Soc 54: 1163-1166, 1932.
18. Milacic V, Chen D, Ronconi L, Landis-Piwowar KR, Fregona D and Dou QP: A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts. Cancer Res 66: 10478-10486, 2006.
19. Chen D, Cui QC, Yang H and Dou QP: Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res 66: 10425-10433, 2006.
20. Chen D, Daniel KG, Chen MS, Kuhn DJ, Landis-Piwowar KR and Dou QP: Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. Biochem Pharmacol 69: 1421-1432, 2005.
21. Gao G and Dou QP: N-terminal cleavage of Bax by calpain generates a potent proapoptotic 18-kDa fragment that promotes Bcl-2-independent cytochrome C release and apoptotic cell death. J Cell Biochem 80: 53-72, 2000.
22. Wood DE and Newcomb EW: Cleavage of Bax enhances its cell death function. Exp Cell Res 256: 375-382, 2000.
23. Pink JJ, Wuerzberger-Davis S, Tagliarino C, Planchon SM, Yang X, Froelich CJ and Boothman DA: Activation of a cysteine protease in MCF-7 and T47D breast cancer cells during β-Lapachone-mediated apoptosis. Exp Cell Res 255: 144-155, 2000.
24. Landis-Piwowar KR, Milacic V, Chen D, Yang H, Zhao Y, Chan TH, Yan B and Dou QP: The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Drug Resist Update 9: 263-273, 2006.
25. Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M and Dang CV: Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 58: 4342-4348, 1998.
26. Canfield SE, Zhu K, Williams SA and McConkey DJ: Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells. Mol Cancer Ther 5: 2043-2050, 2006.